Human Laminin subunit alpha-2(LAMA2) ELISA kit

Code CSB-EL012726HU
Size 96T,5×96T,10×96T How to order?
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details


This Human LAMA2 ELISA Kit was designed for the quantitative measurement of Human LAMA2 protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 0.78 ng/mL-50 ng/mL and the sensitivity is 0.195 ng/mL.

Target Name laminin, alpha 2
Alternative Names LAMA 2 ELISA Kit; LAMA2 ELISA Kit; LAMA2_HUMAN ELISA Kit; Laminin alpha 2 (merosin congenital muscular dystrophy) ELISA Kit; Laminin alpha 2 ELISA Kit; Laminin alpha 2 chain ELISA Kit; Laminin alpha 2 subunit ELISA Kit; Laminin M ELISA Kit; Laminin M chain ELISA Kit; Laminin subunit alpha-2 ELISA Kit; Laminin-12 subunit alpha ELISA Kit; Laminin-2 subunit alpha ELISA Kit; Laminin-4 subunit alpha ELISA Kit; LAMM ELISA Kit; Merosin heavy chain ELISA Kit
Abbreviation LAMA2
Uniprot No. P24043
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 0.78 ng/mL-50 ng/mL
Sensitivity 0.195 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Signal Transduction
Assay Principle quantitative
Measurement Sandwich
ELISA Data Analysis Watch ELISA data processing video & download Curve Expert if needed
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components.
Gene References into Functions
  1. The LAMA2 Mutation Congenital Muscular Dystrophy showed demyelinating polyneuropathy white matter changes on brain. PMID: 29465610
  2. It was established that the frequency of individuals with the COL13A1*D/*D genotype was higher in the senile age period. The LAMA2*I/*D genotype was predisposing to longevity among women. PMID: 29369589
  3. Using high-throughput technology identify LAMA-2 as a candidate medullary sponge kidney disease biomarker possibly employable in future for the early diagnosis of this disease. PMID: 27914711
  4. Differential protein expression of collagen IV, laminin alpha2, and nidogen-1 indicated basal lamina remodeling develops in ischemic failing versus nonfailing human hearts. PMID: 26756417
  5. Next generation sequencing was found to be useful for molecular diagnosis of a confirmed case of merosin deficient congenital muscular dystrophy. PMID: 26104111
  6. did not find positive association signals of the four single nucleotide polymorphisms in the LAMA2 and EGR1 genes with high myopia PMID: 26984843
  7. By analyzing the gene test we found that compound heterozygous LAMA2 mutation inherited from the parents. One coming from the father was a gross deletion expanding from exon 36 to exon 65. The from the mother was a missense mutation c.1358G>C PMID: 26304763
  8. This report widens the clinical spectrum of cerebral manifestations related with mutations in LAMA2 PMID: 25500573
  9. Data showed miR-29a/c as novel regulators of LAMA2 in ependymoma based on miRNA-mRNA covariation and sequence-based target predictions. PMID: 25958202
  10. This study demonstrates a wide clinical spectrum of LAMA2-related muscular dystrophy and its prevalence in an LGMD2 cohort, which indicates that LAMA2 muscular dystrophy should be included in the LGMD2 nomenclature. PMID: 25663498
  11. Crystal structure of LAMM L4 domain PMID: 25962468
  12. Data find high frequency mutations in LAMA2 protein in hepatocellular carcinoma (HCC) patients. Its lower expression levels correlate with tumor progression, poor survival and higher chance of cancer recurrence. PMID: 25159915
  13. Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. PMID: 24804215
  14. 2 patients with partial laminin-alpha2 deficiency and atypical phenotypes, one with almost exclusive central nervous system involvement and second with cardiac dysfunction, rigid spine syndrome and limb-girdle weakness; both have 2 heterozygous LAMA2 variants sharing a potentially pathogenic missense mutation c.2461A>C located in exon 18 PMID: 24534542
  15. Genetic association studies identified two pathogenic mutations in the LAMA2 gene in patients with congenital muscular dystrophy. PMID: 24225367
  16. Homozygous truncating mutations in POMK lead to congenital muscular dystrophies with secondary merosin deficiency, hypomyelination and intellectual disability. PMID: 24556084
  17. children with LAMA2 congenital muscular dystrophy may be at nogreater risk of developing malignant hyperthermia than the general population PMID: 24628934
  18. Identification of cell adhesive sequences in the N-terminal region of the laminin alpha2 chain. PMID: 22654118
  19. Aberrant methylation at target CpG sites in GABRA1 and LAMA2 was observed with high frequency in tumor tissues. PMID: 22038115
  20. This largest series of patients with limb-girdle muscular dystrophy due to laminin alpha2-deficiency expands the clinical phenotype associated with LAMA2 mutations. PMID: 21953594
  21. This is the first report to describe dilated cardiomyopathy with conduction defects and merosin deficiency in a patient carrying LAMA2 gene mutations. PMID: 22006699
  22. A single base deletion at position 8005 in the LAMA2 gene is associated with a severe form of classical congenital muscular dystrophy and partial merosin deficiency in congenital muscular dystrophy type 1A. PMID: 20477750
  23. LAMA2 mutations were found in three different Russian families with congenital muscular dystrophy. PMID: 20607928
  24. This large study identified novel LAMA2 mutations and highlights the role of immunohistochemical studies for merosin status in predicting clinical severity of MDC1A. PMID: 20207543
  25. Data show that the expression of collagen types I, III and fibronectin was significantly higher in pancreatic cancer, and the expression of collagen type IV, laminin and vitronectin was significantly lower in pancreatic cancer. PMID: 19893454
  26. Ku70 is a regulator of Bax-mediated pathogenesis in laminin-alpha2-deficiency muscle cells. PMID: 19692349
  27. case series and review of laminin alpha2(merosin) deficiency phenotypes and abnormalities PMID: 11584042
  28. A number of mutations are identified in association with congenital muscular dystrophies. PMID: 11938437
  29. Merosin-deficient congenital muscular dystrophy with mental retardation and cerebellar cysts, unlinked to the LAMA2 locus in three Tunisian patients. PMID: 12467726
  30. In nine congenital muscular dystrophy patients with abnormal white-matter signal at brain MRI and partial deficiency of muscle laminin alpha 2, three novel missense and two splice-site mutations were found. PMID: 12552556
  31. However, dy(W)/dy(W) mice, expressing the human laminin alpha2 under the control of the striated muscle-specific portion of the desmin promoter, still developed muscular dystrophy. PMID: 12609502
  32. A mild case of autosomal recessive congenital muscular dystrophy is associated with a homozygous out-of-frame deletion in exon 56 of the LAMA2 gene. PMID: 15452315
  33. DNA analysis can be used to provide accurate prenatal diagnosis of thecongenital muscular dystrophy, and have an essential role in genetic counseling. PMID: 16084089
  34. identified 9 new LAMA 2 mutations PMID: 16216942
  35. A relocalization of LAMA2 was noted in the subepithelial basement membrane in a group of Hirschsprung patients. PMID: 16226104
  36. suggest that LNalpha1 chain in part ameliorates the development of LNalpha2 chain deficient muscular dystrophy by retaining the binding sites for integrin alpha7Bbeta1D and alpha-dystroglycan, respectively PMID: 16504180
  37. Study summarizes recent progress concerning the molecular mechanisms of laminins in development and disease. PMID: 17426950
  38. intron mutation is responsible for complete exon 17 skipping in severe congenital muscular dystrophy PMID: 18053718
  39. the first fully characterized gross deletion in the LAMA2 gene, encompassing exon 56 (c.7750-1713_7899-2153del), detected in 31% of congenital muscular dystrophy type 1A patients PMID: 18700894
  40. In patient 1, a double mutation, c.[9101_9104dupAACA:3412G>A] p.[H3035QfsX4:V1138M] was detected, Patient 2 had a novel homozygous nonsense mutation, c.2907C>A (p.Cys969X), in exon 21. PMID: 19294599
  41. Crystal structure shows that the three LG domains adopt typical beta-sandwich folds, with canonical calcium binding sites in LG1 and LG2. LG2 and LG3 interact through a substantial interface, but LG1 is completely dissociated from the LG2-3 pair. PMID: 19553699

Show More

Hide All

Involvement in disease Merosin-deficient congenital muscular dystrophy 1A (MDC1A)
Subcellular Location Secreted, extracellular space, extracellular matrix, basement membrane. Note=Major component.
Tissue Specificity Placenta, striated muscle, peripheral nerve, cardiac muscle, pancreas, lung, spleen, kidney, adrenal gland, skin, testis, meninges, choroid plexus, and some other regions of the brain; not in liver, thymus and bone.
Database Links

HGNC: 6482

OMIM: 156225

KEGG: hsa:3908

STRING: 9606.ENSP00000400365

UniGene: Hs.200841

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1